Please select an option below to help us tailor your newsletter to best suit your content interests!
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
VIEW TRIAL ON CLINICALTRIALS.GOVUrothelial, Transitional cell carcinoma, Bladder cancer, ureter, urethra
Stage 4
Phase 3
Open to Enrollment
1st
Disitimab Vedotic
Anti-body drug conjugate against HER2
Dan Vaena, MD
Seagen Inc.
urothelial carcinoma
Inclusion Criteria:
Exclusion Criteria:
Central nervous system (CNS) and/or leptomeningeal metastasis. Participants with treated CNS metastases are permitted if all of the following are met.
A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)
VIEW TRIAL ON CLINICALTRIALS.GOVBladder cancer, urothelial carcinoma
Stage 4
Phase 1
Open to Enrollment
Evorpacept
Fusion protein blocking CD47-SIRPalpha
Dan Vaena, MD
ALX Oncology
Urothelial carcinoma
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, HER2 positive
Stage 2
Phase 3
Open to Enrollment
N/A
Atezolizumab
PD-L1 inhibitor
Greg Vidal, MD, PhD
Roche/Genentech
HER2 positive early breast cancer
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, ER positive breast cancer
Stage 2
Phase 3
Open to Enrollment
Adjuvant
chemotherapy, ovarian suppression, and endocrine therapy
chemotherapy, ovarian suppression, and endocrine therapy
Greg Vidal, MD, PhD
NRG Oncology
adenocarcinoma
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple negative breast cancer, TNBC
Stage 3
Phase 3
Open to Enrollment
Adjuvant
datopotamab deruxtecan (Dato-DXd)
ADC, Trop2 with Topo1 inhibitor payload
Greg Vidal, MD, PhD
AstraZeneca
Triple negative, ER negative, PR negative, HER2 negative
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast Cancer, MBC, IBC
Stage 4
Phase 3
Open to Enrollment
2nd line endocrine
Giredestrant
SERD
Greg Vidal, MD, PhD
Genentech, Inc.
ER positive, HER2 negative
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, ER+ breast cancer, HER2 negative breast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
Failure of single-agent endocrine therapy
Giredestrant
SERD
Greg Vidal, MD, PhD
Hoffmann La-Roche
ER+, HER2 -
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st
Giredestrant, Phesgo, taxane
SERD, anti-HER2
Saradasri Wellikoff, MD
Roche
HER2 positive, ER positive
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st or 2nd line
Sacituzumab govitecan-hziy
Trop-2 antibody drug conjugate
Greg Vidal, MD, PhD
Gilead Sciences
Triple negative; TNBC
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
VIEW TRIAL ON CLINICALTRIALS.GOVBreast cancer, IBC
Stage 4
Phase 3
Open to Enrollment
1st line
Sacituzumab govitecan, pembrolizumab
Trop-2 antibody drug conjugate, PD-1 inhibitor
Greg Vidal, MD, PhD
Gilead Sciences
TNBC, PD-L1 positive
A Phase 1b/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Triple Negative Breast Cancer, TNBC
Stage 4
Phase 1
Open to Enrollment
2nd Line
Atezolizumab with Ipatasertib or ladiratuzumab-vidotin or Bevacizumab or Cobimetinib or Capecitabine or Combination Chemo
PD-L1 antibody with either PI3Ki or LIV1A ADC or MEKi or VEGFRi or chemo
Greg Vidal, MD, PhD
Hoffman-La Roche
ER- (negative), PR- (negative), HER2- (negative)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)
VIEW TRIAL ON CLINICALTRIALS.GOVbreast cancer
Stage 4
Phase 2
Open to Enrollment
first or second
Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib, Everolimus
multiple
Gregory Vidal, MD
Hoffmann-La Roche
ER+
A Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC)
VIEW TRIAL ON CLINICALTRIALS.GOVCervical cancer, cervix
Stage 2
Phase 3
Open to Enrollment
N/A
Robotic hysterecomty
N/A
Michael Ulm, MD
GOG (Gynecologic Oncology Group)
Adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma (including glassy cell)
Inclusion Criteria:
Exclusion Criteria:
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
VIEW TRIAL ON CLINICALTRIALS.GOVColon
Stage 3
Phase 3
Open to Enrollment
Adjuvant
FOLFOX vs FOLFIRINOX vs active surveillance
chemo
Noam VanderWalde, MD
NRG
Adenocarcinoma
An open-label, multicenter, randomized Phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Rectum, Colorectal
Stage 4
Phase 3
Open to Enrollment
Encorafenib, cetuximab
BRAF inhibitor, EGFR antibody
Pfizer
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER
VIEW TRIAL ON CLINICALTRIALS.GOVColon cancer, rectal cancer, colorectal cancer
Stage 4
Phase 2
Open to Enrollment
1st Line
encorafenib, cetuximab, pembrolizumab
BRAF inhibitor, EGFR mAb, PD-1 inhibitor
Brad Somer, MD
Pfizer
BRAF V600 mutant, MSI-h, dMMR
A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)
VIEW TRIAL ON CLINICALTRIALS.GOVColon cancer, rectal cancer, colorectal cancer
Stage 4
Phase 2
Open to Enrollment
1st or later
pembrolizumab/quavonlimab, pembrolizumab/favezelimab, pembrolizumab/vibostolimab, pembrolizumab+MK-4830
Various immunotherapy combinations
Brad Somer, MD
Merck Sharp and Dohme
Adenocarcinoma, MSI-h, dMMR
Endometrial, uterine
Stage 3
Phase 3
Open to Enrollment
1st Line
Trastuzumab or trastuzumab/pertuzumab
HER2 antibody
Todd Tillmanns, MD
NRG Oncology
Serous carcinoma or carcinosarcoma
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
VIEW TRIAL ON CLINICALTRIALS.GOVEndometrial
Stage 4
Phase 3
Open to Enrollment
Maintenance
Selinexor
Selective inhibitor of nuclear export (SINE)
Todd Tillmanns, MD
Karyopharm Therapeutics, Inc
Endometrioid, serous, undifferentiated, or carcinosarcoma
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
VIEW TRIAL ON CLINICALTRIALS.GOVGastric, Gastroesophageal, esophageal, stomach, esophagus
Stage 4
Phase 3
Open to Enrollment
1st Line
Bemarituzumab, nivolumab
FGFR2b antibody, PD-1 inhibitor
Brad Somer, MD
Amgen
Adenocarcinoma
EF-32 (TRIDENT): Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
VIEW TRIAL ON CLINICALTRIALS.GOVGlioblastoma multiforme, brain cancer
Stage 4
Phase 3
Open to Enrollment
Following debulking surgery
Optune Tumor Treating Fields
Electric field generation
Manjari Pandey, MD
NovoCure GmbH
GBM
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVHead and Neck cancer, oropharyngeal cancer, papillary squamous cell cancer
Stage 2
Phase 3
Open to Enrollment
Definitive chemoradiation
De-instensified XRT, nivolumab
Noam VanderWalde, MD
NRG Cooperative Group
Squamous cell, HPV positive
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels
VIEW TRIAL ON CLINICALTRIALS.GOVLung Cancer, Non-small cell lung cancer, NSCLC
Stage 4
Phase 3
Open to Enrollment
1st Line
Fianlimab
Anti-LAG-3 antibody
Jason Porter, MD
Regeneron Pharmaceuticals
Non-small cell lung cancer
A Phase 2 Trial of MRTX849 in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
VIEW TRIAL ON CLINICALTRIALS.GOVNon small cell lung cancer (NSCLC)
Stage 4
Phase 2
Open to Enrollment
1st Line
MRTX849 (adagrasib), Pembrolizumab
KRAS G12C inhibitor, PD-1 inhibitor
Jason Porter, MD
Mirati Therapeutics Inc.
Non-small cell lung cancer, KRAS G12C mutation
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting
VIEW TRIAL ON CLINICALTRIALS.GOVDiffuse large B-cell lymphoma, follicular lymphoma
Stage 4
Phase 2
Open to Enrollment
3rd Line
Epcoritamab
CD3 and CD20 bispecific Ab
Jason Chandler, MD
Abbvie
DLBCL, follicular lymphoma
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Cutaneous Melanoma
Stage 3
Phase 2
Open to Enrollment
Neoadjuvant
Pembrolizumab, MK-7684, V937
Anti-PD-1, Anti-TIGIT, Oncolytic virus
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Relatlimab and Nivolumab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma
Stage 3
Phase 3
Open to Enrollment
Adjuvant
Relatlimab, Nivolumab
LAG3 inhibitor, PD-1 inhibitor
David Portnoy
Bristol Myers Squibb
A Phase 1/2 open-lable rolling-arm umbrella platford design of investigational agents with or without pembrolizumab or pembrolizumab alone in participants with melanoma (KEYNOTE-U02): Substudy 02B.
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Cutaneous Melanoma
Stage 4
Phase 2
Open to Enrollment
1st Line, PD-1 naive
Multiple
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
A Phase 1/2 open-lable rolling-arm umbrella platford design of investigational agents with or without pembrolizumab or pembrolizumab alone in participants with melanoma (KEYNOTE-U02): Substudy 02A.
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma
Stage 4
Phase 2
Open to Enrollment
2nd Line (post PD-1)
Multiple
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
An open-label, multicenter, Phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Skin Cancer, ocular melanoma, mucosal melanoma
Stage 4
Phase 2
Open to Enrollment
2nd
RP1 + nivolumab
Oncolytic virus
Ari VanderWalde, MD
Replimune Inc.
Melanoma
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
VIEW TRIAL ON CLINICALTRIALS.GOVMultiple myeloma
Stage 4
Phase 3
Open to Enrollment
2nd line through 4th line
CC-92480, bortezomib, dexamethadose (480Vd)
CRBN-E3 ligase modulating drug
Jason Chandler, MD
Bristol Myers Squibb
Multiple myeloma
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, Fallopian Tube, Primary Peritoneal
Stage 4
Phase 3
Open to Enrollment
3rd Line
Mirvetuximab soravtansine plus bevacizumab
Ab drug conjugate against folate receptor alpha + VEG-F inhibitor
Todd Tillmanns, MD
Immunogen, Inc.
High grade serous ovarian/primary peritoneal/fallopean tube cancer
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors (pancreatic cohort)
VIEW TRIAL ON CLINICALTRIALS.GOVPancreatic cancer
Stage 4
Phase 2
Open to Enrollment
1st Line
9-ING-41
GSK-3beta inhibitor
Brad Somer, MD
Actuate Therapeutics Inc.
Pancreatic adenocarcinoma
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate Cancer
Stage 4
Phase 3
Open to Enrollment
2nd Line Hormonal Therapy
MK-5684
CYP11A1 inhibitor
Brad Somer, MD
Merck Sharp and Dohme
Castration-Resistant
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
> or - 2nd line
Pembrolizumab, Lenvatinib
PD-1 inhibitor, VEG-F TKI
Dan Vaena, MD
Merck Sharp and Dohme
Prostate Adenocarcinoma without small cell histology
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
1st or later
Pemrbolizumab and Lenvatinib
PD-1 inhibitor, VEGF TKI
Dan Vaena, MD
Merck Sharp and Dohme
Neuroendocrine castration resistant prostate cancer
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
2nd line or greater
Pembrolizumab Vibostolimab coformulation
PD-1 inhibitor + Anti-TIGIT
Dan Vaena, MD
Merck Sharp and Dohme
Adenocarcinoma
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
Treated or de novo
Pembrolizumab, Carboplatin, Etoposide or Carbo/Etoposide alone
PD-1 inhibitor, chemo
Dan Vaena, MD
Merck Sharp and Dohme
Prostate cancer with neuroendocrine features
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
1st Line chemo or later
Pembrolizumab/Vibostolimab
PD-1/anti-TIGIT coformulation
Dan Vaena, MD
Merck Sharp and Dohme
Prostate Adenocarcinoma without small cell histology
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVRectal cancer, CRC
Stage 2
Phase 2
Open to Enrollment
Adjuvant
FOLFIRINOX
Chemotherapy
Noam VanderWalde, MD
Alliance for Clinical Trials in Oncology
Adenocarcinoma
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the
Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus
Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
Renal Cell Carcinoma, Kidney cancer
Stage 3
Phase 3
Open to Enrollment
Adjuvant
Belzutifan
HIF-2a inhibitor
Brad Somer, MD
Merck Sharp and Dohme LLC
clear cell
Inclusion Criteria:
Has intermediate-high risk, high risk, or M1 no evidence of disease (NED) RCC as defined by the following pathological tumor-node metastasis and tumor grading:
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma
VIEW TRIAL ON CLINICALTRIALS.GOVLiposarcoma, sarcoma
Stage 4
Phase 3
Open to Enrollment
Any
Birmigadlin (BI 907828)
MDM2 inhibitor
David Portnoy, MD
Boeringer Ingelheim
Dedifferentiated liposarcoma
Histologically documented locally advanced or metastatic, unresectable (i.e. surgery morbidity would outweigh potential benefits), progressive or recurrent Dedifferentiated liposarcoma (DDLPS), meeting the criteria for an open study cohort:
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
VIEW TRIAL ON CLINICALTRIALS.GOVSquamous cell skin cancer
Stage 4
Phase 2
Open to Enrollment
2nd line
DaRT224
Intratumoral encapsulated radium-224
Noam VanderWalde, MD
Alpha Tau Medical
Squamous cell carcinoma
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVNon-melanoma skin cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma,
Stage 4
Phase 2
Open to Enrollment
No prior PD-1
RP1, nivolumab
oncolytic virus (HSV), PD-1 inhibitor
Ari VanderWalde, MD
Replimune, Inc.
Basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, basosquamous carcinoma, high-grade dermatofibroma protuberans, angiosarcoma of the skin, non-HIV-related Kaposi sarcoma, sebaceous gland carcinome, eccrine carcinomas
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase 2 Platform Trial: Cohort A: Entrectinib in patients with ROS1 fusion-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOV
Solid Tumors except for NSCLC
Stage 4
Phase 2
Open to Enrollment
any
Entrectinib
selective tyrosine kinase inhibitor
Daniel Vaena, MD
Hoffmann-La Roche
Inclusion Criteria:
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase 2 Platform Trial: Cohort B: Entrectinib in patients with NTRK1/2/3 fusion-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVany solid tumors
Stage 4
Phase 2
Open to Enrollment
any
Entrectinib
selective tyrosine kinase inhibitor
Daniel Vaena, MD
Hoffmann-La Roche
Inclusion Criteria:
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase 2 Platform Trial: Cohort C: Alectinib in patients with ALK fusion-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVany solid tumors except for NSCLC
Stage 4
Phase 2
Open to Enrollment
any
Alectinib
selective tyrosine kinase inhibitor
Daniel Vaena, MD
Hoffmann-La Roche
Inclusion Criteria:
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase 2 Platform Trial: Cohort H: Inavolisib (GDC-0077) in patients with PIK3CA multiple mutant-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVSolid Tumors
Stage 4
Phase 2
Open to Enrollment
any
Inavolisib (GDC-0077)
PI3K-p110α (PIK3CA) inhibitor
Daniel Vaena, MD
Hoffmann-La Roche
Inclusion Criteria:
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase 2 Platform Trial: Cohorts I/J: Belvarafenib in patients with BRAF class II mutant/fusion-positive tumors (I) BRAF class III mutant positive tumors (J)
VIEW TRIAL ON CLINICALTRIALS.GOVSolid Tumors
Stage 4
Phase 2
Open to Enrollment
any
Belvarafenib
Type II pan-RAF kinase inhibitor
Daniel Vaena, MD
Hoffmann-La Roche
Inclusion Criteria:
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase 2 Platform Trial: Cohort K: Pralsetinib in patients with RET fusion-positive tumors
VIEW TRIAL ON CLINICALTRIALS.GOVSolid Tumors
Stage 4
Phase 2
Open to Enrollment
any
Pralsetinib
RET tyrosine kinase inhibitor
Inclusion Criteria:
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, lung, colon, prostate, bladder, RCC, kidney, skin, melanoma, gastric, pancreatic, HCC, rectal, sarcoma, head and neck, esophagus, biliary tract
Stage 4
Phase 2
Open to Enrollment
Last line
nab-sirolimus
MTOR inhibitor
Dan Vaena, MD
Aadi Bioscience, Inc.
TSC1 or TSC2 alterations
A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients
with Somatic Homologous Recombination Deficient Advanced or Metastatic
Cancer
solid tumors
Stage 4
Phase 2
Open to Enrollment
any
Niraparib and Dostarlimab
PARP inhibitor + IgG4 humanized monoclonal antibody resulting in PDL1/2 inhibition.
Gregory Vidal, MD
West Cancer Center
somatic HRD deficiency
Metastatic, recurrent, or unresectable solid tumor with a pathogenic, or presumed pathogenic, somatic mutation of one of the following homologous recombination deficiency (HRD) gene mutations: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD54L, RAD51D, FANC/BRIP1, FANCI, FANCL, FANCN(PALB2), BARD1, CHEK1, CHEK2, CDK12, or PPP2R2A.
Participant must have adequate organ function, defined as follows:
h. Male participant agrees to use a highly effective method of contraception (see Section 5.4 for a list of acceptable birth control methods) starting with the first dose of study treatment through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
j. If an appropriate archival tumor tissue sample is not available, patient is willing to undergo a pre-treatment tumor biopsy.
Exclusion Criteria:
Patients with the following malignancies will be excluded:
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, Lung, Colon, Prostate, Bladder, Kidney (renal cell), Ovarian, Endometrial (uterine), Cervical, Head and Neck, Melanoma, GBM, Stomach, Liver (HCC), Pancreatic, Gastric, Esophageal, Sarcoma
Stage 4
Phase 1
Open to Enrollment
Any
TAC-001
T-cell receptor agonist antibody drug conjugate
Dan Vaena, MD
Tallac Pharmaceuticals
Histologic documentation
Inclusion Criteria:
Exclusion Criteria:
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors
Advanced Solid Tumors, renal cell, head and neck cancer (SCCHN), non-small cell lung cancer (NSCLC)
Stage 4
Phase 1
Open to Enrollment
> or = 2nd line
BMS-986315 with either nivolumab or cetuximab
NKG2A inhibitor
Dan Vaena, MD
Bristol-Myers Squibb